RCS - Redx Pharma plc - Redx Presenting at AFDD meeting

Redx PharmaAnnouncement

07/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221107:nRSG4430Fa&default-theme=true

RNS Number : 4430F  Redx Pharma plc  07 November 2022

REDX PHARMA PLC

("Redx" or "the Company")

 

Redx to Present on the Potential of RXC007 in Fibrotic Diseases at the
Antifibrotic Drug Discovery Meeting

 

Alderley Park, UK, 7 November 2022 Redx (AIM:REDX), the clinical-stage
biotechnology company focused on discovering and developing novel, small
molecule, highly targeted therapeutics for the treatment of cancer and
fibrotic disease, today announces that Dr Nicolas Guisot, VP, Drug Discovery
at Redx Pharma, will speak at the Antifibrotic Drug Discovery (AFDD) Meeting
(9-11 November 2022, Boston, MA) and present a poster on the Company's lead
fibrosis asset, RXC007.

 

In the presentation, which will take place on Friday 11 November at 09:30 am
(EST), Dr Guisot will discuss RXC007, focusing on selective Rho-Associated
Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibition in lung fibrosis,
other fibrotic diseases and in cancer- associated fibrosis.

 

In addition to Dr Guisot's presentation, Redx will present a poster at the
AFDD Meeting on Thursday 10 November at 3:00 pm (EST), which details the
potential of RXC007 in the treatment of fibrosis, including for idiopathic
pulmonary fibrosis (IPF) and chronic fibrosing interstitial lung disease
(CF-ILD), where there is robust preclinical efficacy data across disease
models supporting clinical development in these areas.

 

RXC007 is a highly potent, selective and orally-active ROCK2 inhibitor
targeting multiple diseases associated with fibrosis, being developed for
interstitial lung disease, including IPF.  A Phase 2a study assessing RXC007
as a potential treatment for patients with IPF began in October 2022, with
headline data anticipated to be available in H2 2023.

 

Details of the poster presentation are as follows:

 

 Title:     Potential of RXC007, a highly selective Rho-Associated Coiled Kinase 2 (ROCK2)
            inhibitor to tackle fibrotic lung disease

 Day/Date:  Thursday 10 November 2022
 Time:      15.00 EST

 

A copy of the poster will be made available on the Company's website
following the presentation
at: https://www.redxpharma.com/scientific-publications/
(https://www.redxpharma.com/scientific-publications/)

 

 

 For further information, please contact:

 Redx Pharma Plc                                                     T: +44 (0)1625 469 918

 UK Headquarters

 Caitlin Pearson, Head of Communications

 ir@redxpharma.com (mailto:ir@redxpharma.com)

 Lisa Anson, Chief Executive Officer

 US Office

 Peter Collum, Chief Financial Officer

 SPARK Advisory Partners (Nominated Adviser)                         T: +44 (0)203 368 3550
 Matt Davis/ Adam Dawes

 WG Partners LLP (Joint Broker)                                      T: +44 (0)203 705 9330
 Claes SpŒng/ Satheesh Nadarajah/ David Wilson

 Panmure Gordon (UK) Limited (Joint Broker)                          T: +44 (0)207 886 2500
 Rupert Dearden/ Freddy Crossley/ Emma Earl

 FTI Consulting                                                      T: +44 (0)203 727 1000
 Simon Conway/ Ciara Martin

 

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on
the discovery and development of novel, small molecule, highly targeted
therapeutics for the treatment of cancer and fibrotic diseases, aiming
initially to progress them to clinical proof of concept before evaluating
options for further development and potential value creation. Redx's lead
oncology product candidate, the Porcupine inhibitor RXC004, being developed as
a targeted treatment for Wnt-dependent cancers, commenced a Phase 2 programme
in November 2021. The Company's lead fibrosis product candidate, the
selective ROCK2 inhibitor RXC007, is in development for interstitial lung
disease and commenced a Phase 2a trial for idiopathic pulmonary fibrosis
in October 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK
inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in
pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.

 

The Company has a strong track record of discovering new drug candidates
through its core strengths in medicinal chemistry and translational science,
enabling the Company to discover and develop differentiated therapeutics
against biologically or clinically validated targets. The Company's
accomplishments are evidenced not only by its two wholly-owned clinical-stage
product candidates and rapidly expanding pipeline, but also by its strategic
transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly following its
acquisition of Loxo Oncology and AZD5055/RXC006, a Porcupine inhibitor
targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF),
which AstraZeneca is progressing in a Phase 1 clinical study. In addition,
Redx has forged collaborations with Jazz Pharmaceuticals, which includes
JZP815, a preclinical pan-RAF inhibitor which has received IND clearance from
the US FDA, and an early stage oncology research collaboration.

 

To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRBDBLUGDGDS